Observational studyBMC infectious diseases2025
Investigation of the effect of serum gasdermin d levels on clinical course and mortality in patients with covid-19.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCytokine storm is among the pathogenetic mechanisms in patients with severe Coronavirus Disease 2019 (COVID-19). Pyroptosis, a form of programmed cell death, is thought to play an important role in cytokine storms. Gasdermin D (GSDMD) is the principal protein involved in this pathway. This study aimed to investigate the effect of serum levels of GSDMD on clinical course and mortality in patients with COVID-19.
methodsThis study was designed as an observational, prospective, non-interventional and single-center study, and patients admitted to pandemic intensive care units, wards, and outpatient clinics between December 2020 and August 2021 were included in the study. The study population consisted of 165 patients. The patients were divided into four groups: those admitted to the outpatient clinic (n = 23), those who were followed up on the ward (n = 86), those hospitalized in the intensive care unit (n = 36), and healthy controls (n = 20). Human Gasdermin D ELISA kits (FineTest®) were used to detect Gasdermin D from patients’ serum samples.
resultsHigh Gasdermin D levels in patients with COVID-19 were associated with the need for intensive care, MV, NIMV, increased need for steroids, and mortality. With ROC analysis, Gasdermin D values of 1.45 ng/mL and above were found to be significant in indicating MAS with 63.4% sensitivity and 69.2% specificity (p = 0.002).
conclusionsGasdermin D which is the main protein of pyroptosis, has been the subject of much research in recent years. Our study demonstrated that GSDMD may serve as a useful biomarker for predicting disease progression in patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.